These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. On 'jumbo' and 'junkie' trials. A fumbled affair, a jungle, or the ultimate solution? Hugenholtz PG Eur Heart J; 1991 Feb; 12(2):101-2. PubMed ID: 1904349 [No Abstract] [Full Text] [Related]
4. Laboratory and clinical experience with recombinant plasminogen activator. Builder SE; Grossbard E Prog Clin Biol Res; 1986; 211():303-13. PubMed ID: 3083430 [No Abstract] [Full Text] [Related]
5. [Reperfusion after acute myocardial infarct with fibrinolytic therapy o combination reduced fibrinolytic therapy and a glycoprotein IIb/IIIa inhibitor: the GUSTO V study]. Franzosi MG Ital Heart J Suppl; 2001 Sep; 2(9):1034-6. PubMed ID: 11675828 [No Abstract] [Full Text] [Related]
6. Genentech falls at the last fence in race to market heart drug. Anderson A Nature; 1987 Jun 11-17; 327(6122):450. PubMed ID: 3108670 [No Abstract] [Full Text] [Related]
12. Hepatocyte growth factor plasma levels after myocardial infarction are not affected by recombinant tissue-type plasminogen-activator therapy. Molnar C; Buratti T; Wiedermann CJ; Tilg H Eur Cytokine Netw; 2000 Mar; 11(1):87-90. PubMed ID: 10705304 [TBL] [Abstract][Full Text] [Related]
13. Recombinant human tissue plasminogen activator without heparin is effective in the treatment of hepatic veno-occlusive disease. Gherlinzoni F; Vianelli N; Valdrè L; Catani L; Tani M; Tura S Haematologica; 1999 Feb; 84(2):191-2. PubMed ID: 10091426 [No Abstract] [Full Text] [Related]